Athens, 27.03.2024

An agreement was announced for the participation of the VIANEX Group in the share capital of iDNA.

Innovative solutions that expand the products and services of the VIANEX Group for the benefit of patients.

The VIANEX Group is entering into a strategic partnership with the 2 Greek genetics companies iDNA Genomics and iDNA Laboratories, on a medical and commercial level respectively, which are active in the field of Precision Medicine and Genomic Analysis (DNA Test) with the aim of providing personalised health care services.

Through this partnership and by participating in iDNA’s share capital, the VIANEX Group will expand its activity in the field of prevention and promote innovation in the health sector through products considered pioneering and help both in the prevention of severe conditions, such as cardiovascular diseases, as well as in the treatment of chronic conditions such as depression and obesity.

These products result from an extensive research and development efforts and have received international recognition as well as CE IVD certification. Additionally, state-of-the-art scientific knowledge and cutting-edge laboratory equipment are utilized in their production. The VIANEX Group undertakes the promotion of genetic analyses at the Greek and global level.

Genetic analyses are addressed to Healthcare Professionals aiming at the customisation of clinical care by checking for genetic predispositions to diseases, as well as response to medication. For the VIANEX Group, the power of knowledge and the evolution of science are the driving force for expanding and improving its services to Healthcare Professionals for the benefit of patients.

On the occasion of the investment, Mr. Dimitris Giannakopoulos, President & CEO of VIANEXstated:“At the VIANEX Group, we are going through the second century of our history and we are still in constant search for innovative solutions in the field of health and medicine. We are pleased to expand our activity in the field of prevention by partnering with iDNA to promote innovative and certified products that will make it easier for healthcare scientists to find personalised treatment for patients.”».

Accordingly, Mr. Fotis Sakellaridis, Founder and Chairman of iDNA said: "At iDNA we are excited to partner with the VIANEX Group. We have tried and succeeded as a company to create and certify in Europe products of high innovation and unique technology, which can offer treatment solution to patients and prevention to healthy people. This new strategic partnership opens a Greek company to an excellent growth perspective both in our country and in the global market.”. »